Extended adjuvant therapy: the role of subset analyses

Affiliations

¹ Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address: kathy.pritchard@sunnybrook.ca.

Comment

Kathleen I Pritchard. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):1431-1433.

doi: 10.1016/S1470-2045(17)30787-8. Epub 2017 Oct 12.

¹ Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address: kathy.pritchard@sunnybrook.ca.

No abstract available

Comment on

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Tjan-Heijnen VCG, et al. Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. Lancet Oncol. 2017. PMID: 29031778 Clinical Trial.